RxDoctor Payments Data

Jaishankar Jagadeesan, MD

Internal Medicine · Prentiss, MSNPI 1326149253

Payments from drug & device makers

$882in general payments, 2019–2025

Across 51 payments — averaging $17.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Indivior Inc.$178
  • Boehringer Ingelheim$117
  • AstraZeneca$87
  • Takeda Pharmaceuticals U.S.A., Inc.$73
  • Lilly USA, LLC$61
  • Novo Nordisk$50
  • plus $318 from 13 others

What the payments were for

  • Food & beverage$882100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$882 in reported general payments places this provider in the 60th percentile of 846 internal medicine providers in Mississippi.

See all internal medicine providers in Mississippi

Medicare billing

Part B allowed, 2024
$80,396
Medicare patients
114
Services billed
1,625

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide110$123,708
JardianceEmpagliflozin86$72,166
LinzessLinaclotide110$69,844
FarxigaDapagliflozin Propanediol103$68,266
JanuviaSitagliptin Phosphate78$54,408
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl234$47,398
TradjentaLinagliptin66$41,581
Tresiba Flextouch U-200Insulin Degludec42$38,770
EliquisApixaban54$36,157
MounjaroTirzepatide27$33,519
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$22,247
ZubsolvBuprenorphine Hcl/Naloxone Hcl12$15,547
Janumet XrSitagliptin Phos/Metformin Hcl18$15,533
Breo ElliptaFluticasone/Vilanterol22$8,297
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$7,349

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$50$123,708110 claims
Boehringer IngelheimJardiance, Tradjenta$117$113,747152 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$87$81,198134 claims
AbbVieLinzess, Synthroid$31$71,247134 claims
MerckJanuvia, Janumet Xr$12$69,94196 claims
PfizerEliquis$11$36,15754 claims
Lilly USA, LLCMounjaro$61$33,51927 claims
GSKTrelegy Ellipta, Breo Ellipta$31$30,54351 claims
Orexo US, Inc.Zubsolv$14$15,54712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 846 internal medicine providers in Mississippi.

Other internal medicine in Prentiss

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →